91�㽶��Ƶ

91�㽶��Ƶ today announced that Christopher Hepler, Manager, 91�㽶��Ƶ Biologics Analytical Development, has been invited to speak on ways to improve assay development at the upcoming CASSS WCBP symposium, which will be held on Jan 28 – 30, 2020.

91�㽶��Ƶ today announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer. Ms. Flynn has also joined the company’s Executive Leadership Team and will report to Alessandro Maselli, 91�㽶��Ƶ’s President and Chief Operating Officer.

91�㽶��Ƶ, a global leader in clinical supply services, today announced the launch of FlexDirect™, a new direct-to-patient service for clinical trials.

91�㽶��Ƶ today announced the completion of the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility in Anagni, Italy.

91�㽶��Ƶ today announced it will host a workshop for drug development consultants titled, “How to Effectively Work with a Development Partner – From a Consultant Standpoint”, at its facility in San Diego, on Jan. 8, 2020.

91�㽶��Ƶ today announced the launch of its new CTSuccess™ clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.

91�㽶��Ƶ today announced that it has completed clinical production of Bridge Therapeutics Inc.’s opioid addiction development therapeutic product, BT-219, and executed an Exclusive Licensing Agreement to use 91�㽶��Ƶ’s proprietary Zydis® orally disintegrating tablet technology.

91�㽶��Ƶ today announced that it has entered into a partnership with Ethicann to formulate a new combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from multiple sclerosis spasticity.

91�㽶��Ƶ today announced that it had entered into a long-term commercial supply agreement with BeiGene, Ltd., a biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.